Confronto

GHRP-2 vs. Sermorelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Crescita

N. CAS

158861-67-7

86168-78-7

Peso molecolare

817.93 g/mol

3358 g/mol

Emivita

0.5 h

0.2 h

Sequenza

D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2

YADAIFTNSYRKVLGQLSARKLLQDIMSR

Meccanismo d'azione

GHRP-2

GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.

Sermorelin

Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.

Base di evidenze

Evidenza più alta

Studio sull'uomo

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	GHRP-2	Sermorelin
Germania	Non approvato	Non approvato
JP	Su prescrizione	—
Stati Uniti	Non approvato	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between GHRP-2 and Sermorelin?: GHRP-2 is classified as "Crescita", while Sermorelin is classified as "Crescita". GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, GHRP-2 or Sermorelin?: The highest available evidence level is "Studio sull'uomo" for GHRP-2 and "RCT sull'uomo" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of GHRP-2 and Sermorelin in Germany and the United States?: Germania: GHRP-2 — Non approvato, Sermorelin — Non approvato. Stati Uniti: GHRP-2 — Non approvato, Sermorelin — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

GHRP-2

Sermorelin

Germania

Non approvato

Su prescrizione

—

Stati Uniti

Non approvato

Solo ricerca

Frequently asked questions

What is the difference between GHRP-2 and Sermorelin?

GHRP-2 is classified as "Crescita", while Sermorelin is classified as "Crescita". GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, GHRP-2 or Sermorelin?

The highest available evidence level is "Studio sull'uomo" for GHRP-2 and "RCT sull'uomo" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of GHRP-2 and Sermorelin in Germany and the United States?

Germania: GHRP-2 — Non approvato, Sermorelin — Non approvato. Stati Uniti: GHRP-2 — Non approvato, Sermorelin — Solo ricerca. These are factual summaries with source and review date on the individual pages.